BVD2-23B6 is an novel therapeutic strategy designed to specifically block human GM-CSF. Engineered through advanced antibody creation methods, this therapy shows high specificity for remarkable effectiveness in https://www.targetmol.com/compound/anti-human-gm-csf-antibody-bvd2-23b6